Summit Therapeutics-Spon ADRSMMT
13F holders, Q1 2024 (March 31)2holders
$4.14avg. 13F price*
At the end of Q1 2024, 2 institutions reported holding Summit Therapeutics-Spon ADR (SMMT) in their 13F filings. The largest holders were Lindbrook Capital, LLC ($2K) and Avior Wealth Management, LLC ($86).
- Company
- Summit Therapeutics-Spon ADR
- CUSIP
- 86627R102
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $86 |
| Exits | 1 | $29K |
Ownership 2 holders
| Lindbrook Capital, LLC | 0.00% | No change | 527 | $2K |
| Avior Wealth Management, LLC | 0.00% | New | 21 | $86 |
"% of holder's portfolio" is SMMT's weight in each manager's 13F, not the share of Summit Therapeutics-Spon ADR the manager owns.